Cargando…
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune c...
Autores principales: | Modena, Alessandra, Ciccarese, Chiara, Iacovelli, Roberto, Brunelli, Matteo, Montironi, Rodolfo, Fiorentino, Michelangelo, Tortora, Giampaolo, Massari, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943092/ https://www.ncbi.nlm.nih.gov/pubmed/27471580 http://dx.doi.org/10.4081/oncol.2016.293 |
Ejemplares similares
-
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder
por: Massari, Francesco, et al.
Publicado: (2015) -
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach
por: Fiorentino, Michelangelo, et al.
Publicado: (2016) -
Acquired hemophagocytic syndrome: comment to the case report
por: Ciccarese, Chiara, et al.
Publicado: (2015) -
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021) -
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
por: Aurilio, Gaetano, et al.
Publicado: (2020)